Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Debopam Samanta has a total of 505 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multiple ictal vocalizations as a novel semiology in generalized epilepsy

    by Sophia Brewer, Sarah Cobb, Debopam Samanta, Christopher Manbeck, Vimala Elumalai, Praveen Kumar Ramani

  • Open Access

    Precision Therapeutics for Monogenic Epilepsies: From Molecular Mechanisms to Disease Modification in Developmental and Epileptic Encephalopathies and Neurodevelopmental Disorders with Epilepsy

    by Debopam Samanta

    Background: Developmental and epileptic encephalopathies (DEEs) and neurodevelopmental disorders with epilepsy (NDD-E) are etiologically heterogeneous conditions historically treated with syndrome-based, symptomatic approaches. Advances in genomic sequencing have identified monogenic causes across more than 900 genes, creating opportunities for mechanism-informed and disease-modifying precision therapies. Methods: For this narrative review, PubMed/MEDLINE and ClinicalTrials.gov were searched through September 2026 using disorder-, gene-, mechanism-, and therapeutic-modality-specific terms to identify mechanism-informed and disease-modifying therapies for monogenic DEEs and NDD-E. Results: Pathogenic mechanisms include gain- or loss-of-function ion-channel abnormalities, altered neurotransmitter receptor/transporter function, impaired synaptic signaling, dysregulated intracellular pathways, metabolic deficiencies, protein misfolding, and transcriptional or epigenetic dysregulation. Across genes such as SCN1A, SCN2A, SCN8A, KCNQ2, KCNT1, KCNA2, CACNA1A, GABA-receptor subunits, SLC6A1, GRIN genes, SYNGAP1, STXBP1, DNM1, SHANK3, TSC1/TSC2, GNAO1, UBE3A, MECP2, and TCF4, therapeutic strategies range from repurposed and mechanism-targeted pharmacologic agents (e.g., sodium- and potassium-channel modulators, mTOR inhibitors) to antisense oligonucleotides, RNA interference, gene replacement or augmentation, transcriptional activation, and genome editing. Several programs have advanced from preclinical proof of concept into early- and late-phase human trials, with variant-specific functional classification increasingly guiding therapy selection, particularly distinguishing gain-of-function from loss-of-function disease. Conclusions: Precision therapeutics are shifting the treatment paradigm for monogenic DEEs and NDD-E from empiric seizure control toward mechanism-based targeting of dysregulated molecular pathways and gene-based disease-modifying therapies. Realizing this potential will require functional variant classification, delivery technologies capable of durable and cell-appropriate target engagement, and trial designs incorporating developmental and biomarker outcomes beyond seizure frequency alone to demonstrate genuine disease modification.

  • Delayed Surgical Evaluation After Drug-Resistant Epilepsy Diagnosis Worsens Outcomes in Children

    by Debopam Samanta, Avery Robert Caraway, Andrew T. Knox, Michael Ciliberto, Shifteh Sattar, Cemal Karakas, Krista Eschbach, Kristen Arredondo, Fernando N. Galan, Janelle Wagner, et al.

    Background and ObjectivesDespite its proven effectiveness, epilepsy surgery for drug-resistant epilepsy (DRE) remains underutilized and frequently delayed. Previous studies of epilepsy duration bef...

  • Open Access

    Ketogenic diet therapy in developmental and epileptic encephalopathies: toward syndrome- and gene-informed precision therapy

    by Debopam Samanta, Christopher Paul Manbeck

    Background: Developmental and epileptic encephalopathies (DEEs) are severe, early-onset, frequently drug-resistant epilepsies in which recurrent seizures and epileptiform activity contribute to cognitive impairment beyond the underlying etiology. Ketogenic dietary therapies (KDTs) exert broad, multimodal antiseizure and neuroprotective effects and occupy a distinct position among nonpharmacologic treatments for DEEs. Objective: To synthesize the evidence for KDT across the principal electroclinical DEE syndromes, an expanding spectrum of gene-specific DEEs, and acute presentations such as febrile infection-related epilepsy syndrome (FIRES) and new-onset refractory status epilepticus (NORSE), with attention to outcome measures, mechanisms, adverse effects, and monitoring. Methods: A narrative review of the literature on the classic ketogenic diet (KD), modified Atkins diet, medium-chain triglyceride diet, and low-glycemic-index treatment in DEEs, drawing on randomized controlled trials, cohort studies, systematic reviews, and meta-analyses. Results: KDT has the strongest and most methodologically rigorous evidence base in infantile epileptic spasms syndrome, including comparative-effectiveness data vs. hormonal therapy, followed by strong consensus supporting early use in epilepsy with myoclonic-atonic seizures. Meaningful benefit has also been reported in Dravet syndrome and, to a somewhat lesser extent, Lennox–Gastaut syndrome. Responses are more variable in early-infantile developmental and epileptic encephalopathy, epilepsy of infancy with migrating focal seizures, developmental and epileptic encephalopathy with spike-wave activation in sleep, and hemiconvulsion–hemiplegia–epilepsy syndrome, with tolerability and long-term adherence often declining over time. In FIRES/NORSE, KDT may serve as an acute anti-inflammatory treatment for super-refractory status epilepticus. Gene-specific responses vary substantially, with the most favorable outcomes observed in transporter-related disorders, followed by conditions involving other membrane-associated proteins, including ion channels and neurotransmitter receptors, whereas disorders affecting cellular structural integrity or homeostatic regulation appear less responsive. Conclusions: KDT has an increasingly well-supported, syndrome- and endpoint-specific role across DEEs. Future research should prioritize comparative-effectiveness trials, standardized outcome measures, predictors of response, better-tolerated formulations, and equitable access to dietary therapy.

  • Epilepsy with myoclonic-atonic seizures: a comprehensive review with emphasis on current and emerging pharmacotherapies

    by Debopam Samanta

    1. Epilepsy with myoclonic-atonic seizures (EMAtS) is a childhood-onset developmental and epileptic encephalopathy (DEE) syndrome that accounts for 1–2% of childhood-onset epilepsies, with a cumula...


  • Phenylbutyrate-Responsive SLC6A1 -Related Neurodevelopmental Disorder Associated With a Familial Variant

    by Odette El Ghawi, Eniya Beemarajan, Debopam Samanta, Praveen Kumar Ramani

    SLC6A1 -related neurodevelopmental disorder is a synaptopathy characterized by developmental delay, epilepsy, and neurobehavioral manifestations with marked phenotypic variability. Variants impair γ-aminobutyric acid (GABA) transporter-1 (GAT-1) folding and trafficking, reducing inhibitory neurotransmission and promoting hyperexcitability. Pharmacologic chaperones such as 4-phenylbutyrate (4-PBA) may restore GAT-1 function. We report a 3-generation family harboring a heterozygous SLC6A1 variant with segregating neurodevelopmental and epileptic phenotypes. The proband presented with drug-resistant developmental and epileptic encephalopathy, multiple seizure types, diffuse epileptiform abnormalities, and global developmental delay. Segregation analysis demonstrated co-segregation of the variant with epilepsy and neurodevelopmental features across affected relatives. Because of persistent seizures despite antiseizure medications, glycerol phenylbutyrate (GPB), a prodrug of 4-PBA, was initiated, resulting in complete seizure freedom and reduction of epileptiform discharges on follow-up electroencephalography. These findings highlight the potential role of genotype-informed precision therapy in SLC6A1 -related disorders and underscore the importance of careful variant interpretation in familial cases.


  • Caring Across Languages: Clinician Perceptions of Variability in US Pediatric Outpatient Epilepsy Care

    by Christina Briscoe, Laura Kirkpatrick, Maria A. Planchart Ferretto, Rebecca Garcia Sosa, Christopher W. Beatty, Gretchen M. Berrios-Siervo, Avantika Singh, Joanna Garcia Pierce, Alisa Khan, Alyssa Coffin, et al.

    Little is known about outpatient language access practices in the United States for children with epilepsy whose families use languages other than English (LOE) for medical care. The Pediatric Epilepsy Research Consortium (PERC) aimed to characterize clinician perceptions of institutional practices by developing and conducting a descriptive survey. We weighted statistical outcomes to equally represent clinician opinion from each center and conducted deductive thematic analysis of open-ended responses. One hundred clinicians from 40 institutions (53.3% institutional response rate) completed the survey. Access to both interpretation and translation services was uneven across PERC institutions. Seizure action plans in all common LOE were available at 15.2% of centers. Despite access to professional interpreters, 61.2% reported using nonprofessional interpretation at times. Qualitative themes included clinician burden, necessary resources, language certification practices, nonprofessional interpretation, translation delays, languages of lesser diffusion, technology use, trust in remote interpretation, language concordance, and perceptions of certification requirements. Findings highlight the need for interventions and guidelines to promote language-access for children with epilepsy whose families use LOE.


  • Variability in recommending epilepsy surgery across Level IV epilepsy centers in the United States

    by Avery R. Caraway, Nancy A. McNamara, Andrew T. Knox, Debopam Samanta, Steven M. Wolf, Edward J. Novotny, Adam P. Ostendorf, Krista L. Eschbach, Dewi F. Depositario‐Cabacar, Cemal Karakas, et al.

    Objective: Surgery is an effective, yet underutilized treatment for children with drug‐resistant epilepsy. Although predictors of surgical outcomes are well described, the decision to recommend surgery varies by institution. We aim to evaluate the rates of not recommending surgery, identify associated patient characteristics, and quantify variability across centers. Methods: We queried the Pediatric Epilepsy Research Consortium Surgery database, a prospective multicenter cohort of children (0–18 years) undergoing initial evaluation for epilepsy surgery. Patients with documented surgical decisions were included. Demographic, clinical, and presurgical evaluation variables were compared by surgical recommendation status. Logistic regression identified factors associated with not recommending surgery. Mixed‐effects models quantified between‐center variability. Results: Among 2480 patients across 29 centers, 532 (21%) were not recommended epilepsy surgery (median center rate 17%, interquartile range [IQR] 10%–28%). After accounting for patient characteristics associated with surgical candidacy, substantial variation in decision‐making remained across centers, with a median twofold difference in the odds of not recommending surgery between otherwise similar patients evaluated at different institutions (Median Odds Ratio = 2.25; Intraclass Correlation Coefficient = .18). The clinical characteristics most strongly associated with not recommending surgery included monthly or less frequent seizures (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.75–2.69), non‐structural etiology (OR 2.02, 95% CI 1.56–2.61), and taking ≤2 anti‐seizure medications (ASMs) (OR 1.67, 95% CI 1.34–2.08, all p 's < .01). These characteristics showed minimal clustering across centers (ICCs < .05). Significance: One in five children evaluated for epilepsy surgery are not recommended to pursue surgical treatment. Although clinical factors influence decision‐making, they do not explain the substantial variation in recommendations across pediatric epilepsy centers. Similar children evaluated at different institutions had significant differences in the odds of not being recommended surgery, suggesting that institutional decision‐making contributes importantly to surgical candidacy.